Table 5.
Trial | Treatment arms | Overall survival | Progression-free survival or TTP | ||||
N | Median (mo) | Statistical comparison | N | Median (mo) | Statistical comparison | ||
Berry, 2002 [69] | mitoxantrone prednisone | 56 | 23 | p = 0.48 | 56 | 8.1 | p = 0.018 (TTP) |
prednisone | 63 | 19 | 63 | 4.1 | |||
Kantoff, 1999 [70] | mitoxantrone | 119 | 12.3 | p = 0.77 | 119 | 3.7 | p = 0.02 (TTP) |
hydrocortisone | 123 | 12.6 | 123 | 2.3 | |||
Tannock, 1996 [71] | mitoxantrone prednisone | 80 | NR | p = 0.27 | NR | ||
prednisone | 81 | ||||||
Weissbach, 1998 [88] | epirubicin | 61 | NR by treatment group | 61 | NR by treatment group | "TTF was longer with mitomycin C vs. EMP (p = 0.037); and vs. epirubicin (p = 0.039) | |
EMP | 54 | 54 | |||||
mitomycin C | 60 | 60 | |||||
Anderström, 1995 [72] | epiribucin MPA | 73 | 11.5 | p = NS | 73 | 7.6 | p = 0.013 (TTP) |
EMP | 72 | 9.5 | 72 | 4.3 | |||
Laurie, 1992 [73] | 5-FU doxorubicin mitomycin C (combined) | 70 | 8.7 | p = 0.025 | NR | ||
5-FU doxorubicin mitomycin C (sequential) | 72 | 7.1 | |||||
Saxman, 1992 [74] | cyclophosphamide doxorubicin methotrexate | 26 high PS 24 low PS | 9.5 6 | p = 0.93 p = 0.51 p = 0.7 (unstratified) | 50 | 6.2* | p = 0.07 (TTP) |
cyclophosphamide | 26 high PS 27 low PS | 9 5 | 53 | 4.4* | |||
Murphy, 1988 [75] | doxorubicin cyclophosphamide | 54 | NR | p = NS | 54 | NR | p = NS |
cisplatin 5-FU cyclophosphamide | 46 | 46 | |||||
methotrexate | 52 | 52 | |||||
Stephens, 1984 [76] | doxorubicin cyclophosphamide | 68 | 6.8 | p = NS | NR | ||
hydroxyurea | 69 | 7 |
*Median values include only patients with partial response or stable disease (n was not reported).
Abbreviations: 5-FU – 5- fluorouracil; EMP – estramustine phosphate; mo – months; MPA – medroxyprogesterone; N – number; NR – not reported; NS – non-significant; PS – performance status; TTF – time-to-treatment failure; TTP – time-to-progression; vs – versus.